For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining artificial intelligence, functional drug testing, and genomic analysis to deliver an individualized, actionable treatment plan to patients and their doctors in two weeks or less. This empowers oncologists with the data, evidence, and concise analysis to support those plans and reduces the social and financial impact of unnecessary treatments. First Ascent Biomedical's unique approach puts patients at the center of their treatment, finding the right combination of FDA-approved drugs unique to them because one in three patients die. First Ascent Biomedical also provides powerful insight to Pharmaceutical companies in biomarker identification for new drug development accelerating drug development and reducing costs.